Angiogenesis is an absolute requirement for tumor growth and metastasis, and is an attractive target for biologically based cancer therapies. Vascular endothelial growth factor (VEGF, VEGF-A) is one of the most potent promoters of angiogenesis whose functions are mainly mediated through the tyrosine kinase receptor VEGFR-2 (also known as KDR or Flk-1). Comparable to solid tumors, there is growing evidence that the VEGF/VEGFR2 signaling pathway plays an important role in leukemic cell growth. [1] [2] [3] [4] Clinical trials with VEGF inhibition in a variety of malignancies are ongoing. The best-studied and most advanced approach to VEGF inhibition is the recombinant humanized monoclonal antibody bevacizumab (BV). We have treated patients with relapsed or refractory acute myeloid leukemia (AML), not qualifying for further intensive cytotoxic chemotherapy, in order to investigate single agent BV in AML. Nine patients were treated between May 2005 and May 2006. All patients signed informed consent before enrollment.
A summary of baseline patient characteristics is shown in Table 1 . Patients were between 46 and 81 years old (median: Figure 2 AZD6244 potentiates the action of ZD6474 in leukemia cells. (a), EOL-1 or MV4-11 cells were cultured with ZD6474 and/or AZD6244 (0.125-1 mM). After 2 days, cell proliferation was measured by thymidine uptake. The percent inhibition was graphed and the concentration of each compound that induced 50, 75 or 90% growth inhibition (IC 50 , IC 75 , IC 90 ) was determined (data not shown). The combination index (CI) of ZD6474 and AZD6244 at various dose effects (IC 50 , IC 75 , IC 90 ) was calculated using the median effect method. CI values less than 1 indicate synergy, a CI equal to 1 indicates an additive effect, and a CI greater than 1 indicates antagonism between the two agents. (b) Cell cycle analysis. EOL-1 cells were cultured with ZD6474 and/or AZD6244 (0.25 mM). After 2 days, the cell cycle distribution of these cells was analyzed. The statistical significance of difference between populations in pre-G1 or S phase of cell cycle induced by either ZD6474 or AZD6244 alone and those induced by a combination of both was determined by one-way analysis of variance 63 years), not medically fit to endure further conventional chemotherapy. Refractory AML was defined as primary resistance against at least two induction therapy regimens or relapsed patients who were refractory against at least one reinduction protocol. Seven patients suffered from refractory AML (three primary induction failure, four refractory to X2 induction regimens, or to reinduction after first relapse). Two patients had AML in first relapse (median duration of first complete remission (CR) 7 months; range 7-9 months) of whom one patient had secondary AML evolved from chronic myelomonocytic leukemia. Cytogenetics was abnormal in seven patients, including trisomy 8 and complex cytogenetics (Table 1). All patients had received dose-intensive infusional ara-C and/or high-dose bolus ara-C in combination with anthracycline or mitoxantrone as induction and/or consolidation regimens. BV (Avastin, Roche Pharma) at a dose of 10 mg/kg body weight was administered as a single i.v. infusion over 60-90 min on days 1, 14 and 35 (cycle 1-3). Acetaminophen and antihistamines (clemastin, ranitidin) were administered before infusion to reduce the risk of allergic reactions.
To assess the clinical and molecular response to VEGF inhibition with BV, bone marrow aspiration and biopsy were performed before the initiation of therapy and before the start of the subsequent course. To investigate the mechanisms of action of BV in the bone marrow biopsies, microvessel density (MVD), cellular expression of VEGF, VEGFR2 and the activation status of VEGFR2 at tyrosine phosphorylation sites 951 and 996 (phosphorylated VEGFR2 [p-VEGFR-2] at Y951 and Y996) were analyzed by immunohistochemical staining as described. 1, 4 Before and one day after each BV infusion, we determined circulating molecular angiogenic factors in peripheral blood such as VEGF protein in citrated plasma, circulating endothelial cells (CECs) and circulating endothelial progenitor cells (CEPCs) by fluorescence activated cell sorting as reported by others. 5, 6 Complete blood cell counts were examined twice a week. Safety was assessed at least weekly by physical examination, recording of vital signs and laboratory tests (hematology, coagulation and clinical chemistry).
During treatment with BV, none of the patients fulfilled the criteria of a partial response, defined as the clearance of at least 50% marrow blasts accompanied by increases in platelet counts and hemoglobin values. In five patients with a pretreatment blast percentage of X90%, no change of blast counts at day 14 and day 35 marrow aspirates and biopsies were observed. One patient showed progressive disease with an increase from 50% blasts pretreatment and 95% blasts after the first cycle on day 14. Only one patient showed a reduction of marrow blasts (40% at presentation; 25% on day 14). Two patients were not 
Table 2
Change in molecular markers and blast cell counts in bone marrow and peripheral blood during BV treatment evaluable after BV treatment due to progressive disease and death. Table 2 summarizes the median and range of bone marrow blast percentage in the nine patients before and after BV. Anti-VEGF therapy with BV did not have any significant effect on blast cell infiltration. In contrast, the level of VEGF expression in the bone marrow significantly decreased during treatment with BV as shown in Table 2 and Figure 1a and b (before BV treatment: median 3.78 (arbitrary units) AU, range 1.5-5.8 AU; after BV treatment: median 2.57 AU, range 1.3-5.0 AU; Wilcoxon test; P ¼ 0.042). However, there was no significant change in VEGFR2 and p-VEGFR2 (Y951 and Y996) expression in the bone marrow, suggesting that phosphorylation at the two different sites of VEGFR2 were not inhibited by BV (see Table 2 ). Furthermore, MVD was not influenced by BV administration, and neither plasma VEGF (measured by ELISA) nor cellular VEGFR2, CECs or CEPCs (measured by flow cytometry) changed significantly (see Table 2 ).
Together, our data demonstrate that the antiangiogenic agent BV had a significant effect on the decrease in cellular VEGF expression in the bone marrow after 1-3 cycles BV without displaying any significant antileukemic activity in this heavily pretreated group and any significant effects on surrogate markers of the antiangiogenic response.
However, BV was well tolerated with a favorable safety profile. In our cohort three patients suffered from pre-existing grade 2 hypertension, and their blood pressure was controlled with escalation of antihypertensive medication (calcium-channel blockers, angiotensin-converting-enzyme inhibitors and diuretics). There were no hypertensive crisis or deaths related to hypertension in this patient cohort. No venous or arterial thromboembolic events, and no bleeding despite low platelet counts or proteinuria was seen. Therefore, our data should not discourage the initiation of studies investigating the potential of combining antiangiogenic treatment strategies with conventional cytotoxic drug regimens. A pilot study exploring this approach has shown promising CR rates in combination with cytarabine and mitoxantrone. 7 Further studies are necessary to define its exact role. For several years chronic lymphocytic leukemia (CLL) has been considered a disease of accumulation of relentless maturelooking malignant monoclonal B cells due to a presumed defect in programmed cell death. However, several observations suggest that CLL cells are not immortal and that they require signals from the microenvironment to maintain viability. Increasing evidence shows that neovascularization plays a role in the biology of CLL. 1 Increased microvessel density in marrow 
